AcuteOralTox-LD50

A predictive in vitro screen for LD50 value

CeeTox is the only company that offers an accurate in vitro determination of the acute oral LD50 dose. CeeTox can help you meet Amendment 7 and REACH directives and reduce the need for in vivo testing with the AcuteOralTox™-LD50 in vitro screen.

Download AcuteOralTox™-LD50 PDF

CeeTox scientists have over a decade of experience creating predictive in vitro models. We evaluate the data results of multiple biochemical assays with a proprietary algorithm that identifies the estimated sustained blood concentration (or C_tox® value) where toxicity would occur in a 14-day repeat dose rat study in vivo. We built upon the proven success of the CeeTox® Panel to develop a new algorithm that predicts LD50value.

The AcuteOralTox™-LD50 panel assesses in vitro results to predict the single dose LD50 value and category of toxicity with a high degree of concordance (>70%) to known in vivo values.

AcuteOralTox™-LD50 provides detailed information on the cytotoxicity of test articles using a multi-parameter, cell-based in vitro model. We use the data to rank-order compounds for cytotoxicity, identify potential subcellular targets and mechanisms of toxicity, and to provide an estimate of acute oral toxicity (the C_Tox LD50 value) based on the OECD system for categorizing chemicals (Very Toxic – Toxic – Harmful – Unclassified).

For more information, please contact us for a consultation. Protocol and sample report will be provided upon request. Our goal is to become an extension of your R&D team and enable you to make better decisions, earlier in discovery, and bring safer products to market.